Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BM2216 extended-release tablets for painful diabetic peripheral neuropathy
CTR20254101Phase 3Active
- Sponsor
- Baimai Biotech
- Start
- Oct 2025
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BM2216 in diabetic polyneuropathy (DPN) (3 arms), sponsored by Baimai Biotech. Primary endpoint: Change from baseline in ADPS at week 14 for BM2216 versus placebo. Started Oct 2025; status: active.
02
Drugs
BM2216
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on CTR20254101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254101.